UK regulatory framework for peptides. Live tracker.
Five regulators set the rules for peptides, collagen and GLP-1 medicines in the UK. We track what they are saying, in plain English, and link to the primary sources.
Last updated: 06 October 2026. Editorial commentary, not legal advice.
The five jurisdictions we track
Each regulator below has a separate remit. We summarise what each one covers, link to our existing deep-dive where it exists, and link directly to official agency sources.
Medicines and Healthcare products Regulatory Agency
Sale and supply of unlicensed medicines without Marketing Authorisation; illegal manufacture and cold-chain import breaches.
World Anti-Doping Agency
Section S0 (Non-approved substances) and S2 (Peptide hormones, growth factors, related substances and mimetics).
Advertising Standards Authority
CAP Code Rule 12.11: Absolute prohibition on advertising prescription-only medicines or unlicensed medicinal products to the public.
Food and Drug Administration
Category 2 bulk substance classification and warning letters for unapproved peptide compounding.
European Medicines Agency
Scientific evaluation of centralized marketing authorization applications for GLP-1 analogues and recombinant peptides.
What UK regulators are saying about peptides and GLP-1 medicines
MHRA welcomes sentencing after fraud convictions over falsely certified medical devices
MHRA grants conditional approval for semaglutide (Wegovy) to treat MASH in adults with moderate to advanced liver fibrosis.
MHRA, ASA and GPhC issue a joint warning on promoting newly licensed prescription-only and unlicensed weight-management medicines.
MHRA approves the first GLP-1 tablet licensed for weight management in the UK. It is prescription-only and cannot be advertised to the public.
Two arrested in the MHRA's largest ever seizure of unlicensed weight-loss medicines. Around 12,000 doses recovered, including retatrutide, tirzepatide and peptide products.
High Court orders six UK internet providers to block websites selling counterfeit and unlicensed semaglutide. Extended on 23 Jun 2026 with dynamic blocking.
MHRA approves a single-dose 7.2mg semaglutide (Wegovy) pen for adults with obesity at a BMI of 30 or above.
GPhC review of weight-management services reports 1,307 concerns over two years. 27% concerned prescribing practice and 17% advertising.
MHRA alert on fake Mounjaro (tirzepatide) KwikPen 15mg pens, batch D873576, dispensed by a Birmingham pharmacy. Sterility cannot be confirmed.
ASA upholds rulings that public discount and referral code posts for online pharmacies advertised prescription-only weight-loss medicines to the public.
MHRA updates semaglutide product information for the very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION).
MHRA updates GLP-1 product information on the small risk of severe acute pancreatitis, after 1,296 Yellow Card reports between 2007 and October 2025.
Per-compound UK legal status pages
Dedicated UK regulatory status summaries for the most-indexed synthetic research peptides and GLP-1 compounds. Each one reviews the Misuse of Drugs Act position, Psychoactive Substances Act status, and MHRA marketing authorization requirements.
The data behind this hub
Trustly Pharma maintains these as refreshable datasets rather than one-off static articles. Each carries its own source, methodology, and last-updated date.
MHRA enforcement and safety tracker →
Every MHRA safety alert, enforcement action, and drug safety update relevant to synthetic peptides and weight-loss medicines, dated and linked back to the gov.uk original.
Source: gov.uk / MHRA · 23 items indexed in rolling 90 daysUK peptide legal classification matrix →
Comprehensive statutory matrix cross-referencing synthetic peptides across HMR 2012, Misuse of Drugs Act 1971, Psychoactive Substances Act 2016, and WADA S0/S2 categories.
Source: UK Statutory Instruments · WADA Prohibited ListPrimary Statutory & Official Sources
Trustly Pharma provides analytical educational commentary. Editorial summaries do not substitute for statutory guidance issued by the UK regulator. Official UK repositories publish primary legislative texts and classification notices for independent verification:
MHRA Products Portal
The Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
Drug Safety Update
The MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
Report an unlicensed or illegally supplied medicine
The MHRA statutory reporting channel for unlicensed sellers supplying prescription products unlawfully, and for submitting intelligence regarding suspected counterfeit reagents.
CAP Code and ASA Rulings
The UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
WADA Prohibited List
The annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
Human Medicines Regulations 2012
The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
How we build this hub
We pull primary-source statements from MHRA, FDA, WADA, EMA and ASA directly. We do not paraphrase secondary reporting. Where a position has shifted, we date the entry and link to the regulator's own page so the reader can verify. Items still pending source confirmation are held back from the ticker until an editor verifies them against the regulator's own published record.
This page is editorial commentary. It is not legal advice. For binding interpretation of any regulator's position, consult the regulator directly or a qualified UK medicines lawyer.